Skip to main content

20th International Myeloma Workshop Main banner

Myeloma Novel Drug Targets and agents

Myeloma Novel Drug Targets and agents

Type here to filter the list

P-175: Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma
P-176: ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
P-177: Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma (MM).
P-178: Evolution of the Multiple Myeloma Treatment Landscape in Portugal: a 5-year longitudinal analysis of treatment patterns in nationwide clinical practice
P-179: Altered Lipid Metabolism in IMiD/CELMoD Resistant Multiple Myeloma Confers Novel and Targetable Vulnerabilities
P-180: PYGO2 is upregulated in multiple myeloma patients with 1q21+ : a potential novel therapeutic target.
P-181: Towards an IMiD sensitive C57BL/KaLwRij murine model of multiple myeloma
P-182: Natural killer cells are active against myeloma cells with loss of tumor suppressor genes
P-183: Bottlebrush prodrugs as triplex combination therapies for multiple myeloma
P-184: Lenalidomide: Rash or no rash, that is the question
P-185: Discovery of Novel Proteasome Activators that Enhance Antigen Presentation and Trigger Anti-myeloma T-cell Immunity
P-186: Proteasome Regulatory ATPase PSMC2 Promotes Drug Resistance by Mitigating ER Stress and Portends Reduced Overall Survival in Multiple Myeloma
P-187: Therapeutically Targeting 19S Proteasome-associated Subunit PSMD1/Rpn2 in Multiple Myeloma
P-188: Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma
P-189: Indirubin Derivative Acts as Dual Inhibitor Targeting Proteasome and Autophagy for Treating Multiple Myeloma
P-190: Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma
P-191: Acquisition of venetoclax resistance is characterized by higher expression of anti-apoptotic regulators, less mitochondrial priming, and broader resistance to anti-MM agents.
P-192: Increased serum CRBN levels are associated with improved survival in MM patients
P-193: Novel antigens LMA and KMA are expressed on malignant bone marrow plasma cells from patients at all stages of multiple myeloma and in other plasma cell dyscrasias
P-194: Non-coding RNA LINC01410 interacts with the minichromosome maintenance (MCM) complex and is a dependency in Multiple Myeloma
P-195: Loss of GABARAP mediates resistance to immunogenic chemotherapy by altering protein trafficking of calreticulin on the cell surface
P-196: IMPACT OF PREFERENTIAL CODONIC LOSS OF ARGININE IN MULTIPLE MYELOMA
P-197: Tissue Factor as a New Target for CAR-NK Cell Immunotherapy of Multiple Myeloma and Triple-Negative Breast Cancer
P-198: Impact of Blocking the CD47 Axis on Phagocytosis of Myeloma Cells Treated with CD38 Antibodies and Proteasome Inhibitors
P-199: Novel Antibodies Identified by Phage Display Induce Direct Myeloma Cell Death
P-200: MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism
P-201: Induction of pyroptosis for the treatment of multiple myeloma
P-202: SLAMF1-derived peptide P7N4-Pen as anti-myeloma treatment
P-203: Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The iinnovate clinical development program
P-204: Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma.
P-205: Heme promotes venetoclax resistance in multiple myeloma
P-206: 3D in vitro modelling of relapsed/refractory multiple myeloma to unveil mechanisms of acquired resistance to therapy
P-207: Targeting iron homeostasis in combination with IMiDs as a therapeutic strategy in Multiple Myeloma
P-208: Infectious Risks in Newly Diagnosed Multiple Myeloma (NDMM) patients receiving (or treated with) daratumumab based regimens: a multicentric Italian experience
P-209: Multiple myeloma-derived circulating extracellular vesicles affect normal human stromal cell behaviour and promote tumor progression: a multi-omic approach
P-210: Novel Pro-Survival Role for Tryptophan 2,3 Dioxygenase 2 in Multiple Myeloma
P-211: Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses.
P-212: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA
P-213: COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
P-214: A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
P-215: Apurinic/apyrimidinic nuclease 1 (APEX1) can impact multiple related pathways to drive growth and genomic instability in myeloma
P-216: The PBK-FOXM1 axis disrupts the DREAM transcriptional repressor complex, contributing to the growth and genomic instability of myeloma
P-217: ULK3-mediated autophagy is a tractable therapeutic target for the treatment of multiple myeloma.
P-218: TLR-activation may promote drug resistance and disease progression in multiple myeloma
P-219: Investigating the Proteasome Stress Response as a Potential Therapeutic Target in Multiple Myeloma
P-220: Discovery of tumor-reactive T cell receptors by functional single cell interaction analyses in patients with newly diagnosed multiple myeloma
P-221: PIM2 kinase regulates TIGIT expression and energy metabolism in NK cells from multiple myeloma patients
P-222: Development of pERp1-ADC as a Novel Therapeutic for Multiple Myeloma